Compare MYND & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYND | LEXX |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 16.3M |
| IPO Year | 2017 | N/A |
| Metric | MYND | LEXX |
|---|---|---|
| Price | $0.44 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 187.4K | ★ 1.5M |
| Earning Date | 08-27-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $209,800,000.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.42 | $0.46 |
| 52 Week High | $2.10 | $2.43 |
| Indicator | MYND | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 42.16 |
| Support Level | $0.42 | $0.46 |
| Resistance Level | $0.48 | $0.72 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.29 | 52.85 |
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.